Literature DB >> 20013887

Resveratrol bioavailability and toxicity in humans.

Charles-Henry Cottart1, Valérie Nivet-Antoine, Christelle Laguillier-Morizot, Jean-Louis Beaudeux.   

Abstract

Numerous data are now available on the beneficial properties of the polyphenolic compound resveratrol including its anti-inflammatory and antitumor effects. However, few studies have been performed with resveratrol in humans, and the results of these studies appear fragmentary and sometimes contradictory due to variations in conditions of administration, protocols and methods of assessment. This review article presents the results of recent studies investigating the pharmacokinetics, bioavailability, and toxicity of resveratrol in humans. Resveratrol is well absorbed, rapidly metabolized, mainly into sulfo and glucuronides conjugates which are eliminated in urine. Resveratrol seems to be well tolerated and no marked toxicity was reported. These data are important in the context of human efficacy studies, and they provide further support for the use of resveratrol as a pharmacological drug in human medicine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20013887     DOI: 10.1002/mnfr.200900437

Source DB:  PubMed          Journal:  Mol Nutr Food Res        ISSN: 1613-4125            Impact factor:   5.914


  148 in total

1.  Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs.

Authors:  Miguel Muzzio; Zhihua Huang; Shu-Chieh Hu; William D Johnson; David L McCormick; Izet M Kapetanovic
Journal:  J Pharm Biomed Anal       Date:  2011-10-25       Impact factor: 3.935

2.  Metabolism and disposition of 2-hydroxy-4-methoxybenzophenone, a sunscreen ingredient, in Harlan Sprague Dawley rats and B6C3F1/N mice; a species and route comparison.

Authors:  Esra Mutlu; C Edwin Garner; Christopher J Wegerski; Jacob D McDonald; Barry S McIntyre; Melanie Doyle-Eisele; Suramya Waidyanatha
Journal:  Xenobiotica       Date:  2019-10-31       Impact factor: 1.908

Review 3.  Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases.

Authors:  Yang Sun; Tuo Yang; Rehana K Leak; Jun Chen; Feng Zhang
Journal:  CNS Neurol Disord Drug Targets       Date:  2017       Impact factor: 4.388

Review 4.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

5.  Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity.

Authors:  Tamara P Kondratyuk; Eun-Jung Park; Laura E Marler; Soyoun Ahn; Yang Yuan; Yongsoo Choi; Rui Yu; Richard B van Breemen; Bin Sun; Juma Hoshino; Mark Cushman; Katherine C Jermihov; Andrew D Mesecar; Clinton J Grubbs; John M Pezzuto
Journal:  Mol Nutr Food Res       Date:  2011-06-29       Impact factor: 5.914

6.  Microfluidic platform integrated with worm-counting setup for assessing manganese toxicity.

Authors:  Beibei Zhang; Yinbao Li; Qidi He; Jun Qin; Yanyan Yu; Xinchun Li; Lin Zhang; Meicun Yao; Junshan Liu; Zuanguang Chen
Journal:  Biomicrofluidics       Date:  2014-09-24       Impact factor: 2.800

Review 7.  Modulation of Inflammatory Response to Implanted Biomaterials Using Natural Compounds.

Authors:  Maria Yanez; James Blanchette; Ehsan Jabbarzadeh
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 8.  Future directions in the prevention of prostate cancer.

Authors:  Ian M Thompson; April B Cabang; Michael J Wargovich
Journal:  Nat Rev Clin Oncol       Date:  2013-11-26       Impact factor: 66.675

9.  Forging a modern generation of polyphenol-based therapeutics.

Authors:  Bernice Wright
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

10.  Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity.

Authors:  Alexandre Dal-Pan; Stéphane Blanc; Fabienne Aujard
Journal:  BMC Physiol       Date:  2010-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.